Journal article
Systematic review of the effectiveness of pharmacologic interventions to improve quality of life and well-being in people with dementia
C Cooper, N Mukadam, C Katona, CG Lyketsos, D Blazer, D Ames, P Rabins, H Brodaty, CDM Lima, G Livingston
American Journal of Geriatric Psychiatry | Published : 2012
Abstract
OBJECTIVE: To review systematically, for the first time, the effectiveness of all pharmacologic interventions to improve quality of life and well-being in people with dementia. DESIGN: Systematic review and meta-analysis. METHODS: We systematically reviewed the 15 randomized controlled trials and one review that fitted predetermined criteria. We included studies that reported the outcomes quality of life, well-being, happiness, or pleasure. MEASUREMENTS: We rated the validity of studies using a checklist. We calculated mean differences between intervention and control groups at follow-up. RESULTS: None of the evaluated trials reported a significant benefit to quality of life or well-being fo..
View full abstractGrants
Awarded by National Institute on Aging
Funding Acknowledgements
DB has received grant funding from NIDA and NIMH, National Institutes of Health, USA. GL and LT are each co-authors of one of the reviewed papers. GL has received funding from Lundbeck. HB is grant support/sponsored speaker or advisory board member of NHMRC, Australian Commonwealth Department of Health and Ageing, Pfizer, Eisai, Janssen, Novartis, Lundbeck, Lilly, Medivation, Sanofi, Prana (none relevant to this paper). CGL has received grant support (research or continuing education) from NIMH, NIA, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, Glaxo-Smith-Kline, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, Bristol-Myers, Novartis, National Football League, and Elan; consultant/advisor for Astra-Zeneca, Glaxo-Smith Kline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, NFL Players Association, NFL Benefits Office; honorarium or travel support from Pfizer, Forest, Glaxo-Smith Kline, Health Monitor. CK has undertaken paid lectures, advisory board membership, and received consultancy fees from several pharmaceutical companies including Lilly Lundbeck and Pfizer Eisai; grant funding from Lundbeck; expert testimony on behalf of GSK. PR has provided legal testimony for Janssen Pharmaceutica, and received grant support from NIMH and NIA.